Efficacy and safety of vibegron for treating overactive bladder: a prospective real-world study

Efficacy and safety of vibegron for treating overactive bladder: a prospective real-world study - Efficacy and safety of vibegron

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035771

Enrollment

200

Registered

2019-02-11

Start date

2018-12-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

vibegron 50 mg daily in eight weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patient with overactive bladder

Exclusion criteria

Exclusion criteria: the patient with allergy to beta 3 agonists

Design outcomes

Primary

Measure	Time frame
The change of OABSS score after 8 weeks	—

Countries

Japan

Contacts

Public ContactYuki Kyoda

Sapporo Medical University School of Medicine Department of Urology

kyohday@sapmed.ac.jp011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026